← Back to Clinical Trials
Recruiting NCT05503875

NCT05503875 Immunoclassification of Psoriasis: a Strategy for Precision Medicine

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05503875
Status Recruiting
Phase
Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Condition Immunoclassification
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2023-01-01
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2023-01-01 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Through the combination of clinical manifestations and omics, the investigators aim to explore the skin cell atlas in different stages of psoriasis lesions, establish a clinical classification standard for psoriasis, and guide the precise treatment of psoriasis.

Eligibility Criteria

Inclusion Criteria: 1.18 to 75 years of age 2.Moderate to severe chronic psoriasis, BSA≥3% 3.Duration of psoriasis≥6 months 4.Patients must be candidate for systemic therapy 5.Informed consent must be obtained 6.For female, ß-hCG test is negative and contraception is accepted Exclusion Criteria: 1. Having severe infections, including hepatitis, HIV and tuberculosis 2. Having significant allergies to biological agents 3. Having a history of malignancy 4. Refusal of contraception 5. Having serious or unstable/uncontrolled illnesses

Contact & Investigator

Central Contact

Xiao-yong Man

✉ manxy@zju.edu.cn

📞 13600516219

Frequently Asked Questions

Who can join the NCT05503875 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Immunoclassification. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05503875 currently recruiting?

Yes, NCT05503875 is actively recruiting participants. Contact the research team at manxy@zju.edu.cn for enrollment information.

Where is the NCT05503875 trial being conducted?

This trial is being conducted at Hangzhou, China.

Who is sponsoring the NCT05503875 clinical trial?

NCT05503875 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology